FGF21 and metabolic dysfunction-associated steatohepatitis: Pegbelfermin, a PEGylated human recombinant FGF21 analog, has been evaluated in a phase 2a RCT in patients with NASH, showing a reduction in the hepatic fat accumulation [82].